KONEXBiotech & Pharma251280

AngioLab

₩2,425▲ 0.41%2026-10-02 close

Market Cap

₩8.5B

Turnover

₩1,963,365

Volume

856 shares

Shares out.

3.5M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Oral AMD Drug ALS-L1023 Advances to Phase 3

AngioLab has entered a tangible monetization phase with ALS-L1023's Phase 3 wet-AMD trial underway and a freshly secured 21-country European patent portfolio, positioning the company for potential global licensing deals.

1
ALS-L1023 Phase 3 IND approved by Korea MFDS; Phase 3 for wet AMD underway jointly with Hallim Pharmaceutical and Sangmyung Innovation
2
European patent registered across 21 countries in January 2026 (valid until 2041); active patent filings in the US, China, Japan, Canada, Australia, and Brazil
3
Technology-transfer agreement structured at KRW 11 billion total fee plus royalties; milestone payments recognizable as revenue following Phase 3 IND approval
4
ALS-L1023 Phase 2a for MASH completed with significant improvements in hepatic fat, fibrosis, ALT, and AST; rosacea indication licensed to Biomedicin
5
60-plus patent portfolio; KRX-commissioned technical analysis report published by NICE Ratings (October 2025) providing external institutional validation of technology

Business structure

AngioLab was founded in June 1999 as a bioventure specializing in angiogenesis inhibition and has been listed on the KONEX market since October 2016.

Its business spans three verticals: pharmaceuticals (natural-product and antibody-based), health functional foods, and cosmetics; current revenues are derived from small-scale sales of the latter two, while the pharmaceutical pipeline remains entirely in clinical development.

The lead compound, ALS-L1023, is an oral natural-product drug derived from a Melissa-leaf extract fraction that inhibits key angiogenic factors such as VEGF and bFGF, while additionally carrying anti-inflammatory and antioxidant multi-mechanism properties.

The company pursues a platform approach—deploying the same compound across five indications: wet AMD (Phase 3 ongoing), MASH (Phase 2a completed), secretory otitis media (Phase 2 completed), periodontal disease (Phase 2 completed), and rosacea (pre-clinical completed, licensed).

Phase 2 wet-AMD data showed the proportion of patients achieving at least 15-letter (3-line) visual-acuity improvement was significantly higher than the control group at 12 months, while the MASH Phase 2a demonstrated significant reductions in hepatic fat and fibrosis and improvement in ALT, AST, and total cholesterol versus control.

On technology transfer, AL101-AMD for wet AMD was licensed to Sangmyung Innovation (a Hallim Pharmaceutical subsidiary) for KRW 11 billion total plus royalties, with Hallim designated to handle commercial distribution post-approval; the rosacea indication was separately licensed to Biomedicin.

Operating from Daejeon with approximately 16 employees and no consolidated subsidiaries, the company maintains a lean cost structure while concentrating research capabilities.

A portfolio of more than 60 patents underpins its domestic and international IP defense, covering rights across angiogenesis-related and MMP-enzyme-related diseases, preserving protection as the platform expands.

Recent trends

AngioLab trades in an extremely illiquid environment even by KONEX standards, with daily trading value hovering around KRW 1 million; as of June 7, 2026, the share price stood at KRW 1,900 (up 0.26% day-on-day) with a market capitalization in the low billions of Korean won.

The company relies on small-scale health functional food and cosmetics sales for revenues, with reported annual revenues of approximately KRW 500 million, resulting in a structural deficit where R&D expenditures substantially exceed revenues.

According to FnGuide data, on a standalone basis in 2023 revenues fell 50.6% year-over-year while operating losses widened by 16.3% and net losses by 15.4%, consistent with a pre-commercial R&D profile.

The 26th Annual Business Report filed on March 18, 2025, for the fiscal year ending December 31, 2024, confirms single-entity operations with no consolidated subsidiaries; core assets comprise the clinical-stage pipeline and patent portfolio.

The primary near-term revenue recognition trigger is the KRW 11-billion technology-transfer agreement with Hallim Pharmaceutical, under which upfront fees become recognizable following Phase 3 IND approval.

In January 2026, the ALS-L1023 Melissa-leaf fraction patent was successfully registered across 21 European countries under the EU Unitary Patent System and through separate validations in the UK, Spain, and Switzerland, with rights valid until 2041.

In October 2025, NICE Ratings published a KRX-commissioned technical analysis report as part of the exchange's investment information support program for smaller listed companies, providing a measure of external institutional validation.

The ongoing Phase 3 wet-AMD trial is managed through a joint R&D committee with Hallim Pharmaceutical and Sangmyung Innovation, with Hallim designated for post-approval commercial distribution.

Outlook

The most critical near-term catalyst is the pace of the ALS-L1023 Phase 3 wet-AMD trial and any interim data readouts.

A successful Phase 3 outcome would open a commercial path as Korea's first oral AMD therapy, enabling AngioLab to target combination-therapy use cases or patients with insufficient response to existing anti-VEGF injectables such as Lucentis, Eylea, and Vabysmo.

With patent filings active in the US, China, Japan, Canada, Australia, and Brazil, the completion of a global IP defense network anchored by the European patent would substantially strengthen leverage in overseas licensing negotiations with large pharmaceutical companies.

The MASH field remains one of the highest-priority areas for global pharmaceutical investment; a global partnering deal built on the positive Phase 2a data could yield a meaningful upfront payment.

A potential KOSDAQ listing remains a stated strategic option, and if realized would improve access to institutional capital and broaden the investor base.

However, given typical Phase 3 timelines of three to five or more years and ongoing R&D cost burdens, meaningful revenue conversion should be assessed on a medium-to-long-term horizon, and the mechanism for bridging operating cash needs in the interim remains a key variable for investor dilution risk.

Bull factors

Oral Delivery Differentiation: Unique AMD Franchise on Phase 3 Success

All existing wet-AMD treatments—Novartis's Lucentis, Bayer/Regeneron's Eylea, and Roche's Vabysmo—require intravitreal injections, imposing significant patient discomfort and recurring procedural burden.

ALS-L1023's oral delivery mode represents a clear differentiation, backed by Phase 2 data confirming visual-acuity improvement in combination with Lucentis, enabling targeting of patients with insufficient response to existing therapies or injection-related tolerance issues.

A successful Phase 3 outcome would enable rapid domestic market penetration via Hallim Pharmaceutical's established sales network while simultaneously accelerating recruitment of a global commercialization partner.

This constitutes a single clinical event capable of multi-dimensionally re-rating the company's enterprise value.

Multi-Indication Platform: Diversifying Value from a Single Compound

The single-compound, five-indication platform structure—covering AMD, MASH, periodontal disease, secretory otitis media, and rosacea—provides meaningful risk diversification, as failure in any one clinical program does not extinguish total enterprise value.

MASH is one of the most intensely contested areas in global drug development, with billions of dollars invested by major pharmaceutical companies; a global partnering deal built on the positive Phase 2a data could yield a substantial upfront payment.

The rosacea indication has already entered a commercial path via the Biomedicin license, and periodontal disease and otitis media, post-Phase 2, hold open options for further licensing or independent commercialization.

Expanding Global IP Portfolio Strengthens Licensing Leverage

The January 2026 registration of a 21-country European patent (valid until 2041) secures exclusive rights across European markets, complemented by active filings in the US, China, Japan, Canada, Australia, and Brazil.

Once this global IP defense network is completed, AngioLab's negotiating position in technology-transfer and co-development discussions with major overseas pharmaceutical companies will be substantially enhanced.

The EU patent, layered atop an existing portfolio of over 60 patents, covers rights across angiogenesis-related diseases and MMP-enzyme-related conditions, preserving IP protection as the platform is extended to new indications.

Bear factors

Structural Operating Losses and Constrained Financing Capacity

AngioLab generates approximately KRW 500 million in annual revenues, and its 2023 revenues fell 50.6% year-on-year, reflecting very weak monetization from commercial product lines.

The structural deficit—where R&D expenditures substantially exceed revenues for this 16-person organization—is likely to persist throughout the Phase 3 trial period, requiring additional capital.

In a KONEX environment where daily trading value averages barely KRW 1 million, raising equity through secondary markets is effectively constrained, elevating the risk of shareholder dilution via convertible bonds or rights offerings.

Phase 3 Failure and Timeline Extension Risk

Phase 3 trials typically require three to five or more years to complete and carry substantially lower success rates than Phase 2—a well-documented pattern in pharmaceutical development.

Even with positive Phase 2 results, ALS-L1023 could fail to demonstrate sufficient efficacy or safety in Phase 3, which would likely trigger a sharp decline in enterprise value.

Unforeseen variables such as trial extension, protocol amendments, or patient enrollment delays could further postpone monetization, leaving shareholders waiting for tangible financial returns for an extended period.

Uncertain Market Penetration Against Established Injectable Therapies

The wet-AMD market is dominated by proven anti-VEGF injectables from global majors—Novartis's Lucentis, Bayer/Regeneron's Eylea, and Roche's Vabysmo—along with their growing biosimilar counterparts, all of which hold entrenched market positions.

For oral administration's convenience to translate into clinical and economic advantages, robust Phase 3 efficacy data are essential, and competition for formulary listing and reimbursement approval presents a further significant hurdle.

Moreover, a small domestic bioventure is structurally limited in marketing resources and commercial capabilities to independently penetrate overseas markets without a large global partner.

Risk factors

Clinical & Regulatory Risk

Phase 3 drug development entails inherently high failure rates, and unforeseen regulatory risks—such as evolving requirements from MFDS or overseas agencies, or demands for additional studies—can materialize unexpectedly.

Discovery of a serious adverse event (SAE) or a structural design flaw mid-trial could necessitate suspension or redesign, directly impairing the value of the company's core asset.

The challenge of managing multiple clinical programs with a small internal team also introduces execution and oversight risk that warrants consideration.

Liquidity & Financing Risk

Operating cash outflows are likely to persist throughout the multi-year Phase 3 trial period, heightening the need for additional external financing.

KONEX's structural liquidity constraints make equity-based capital raises difficult, and reliance on convertible bonds or redeemable convertible preferred shares for funding creates dilution risk for existing shareholders.

Should technology-transfer milestone payments arrive later than expected, insufficient working capital could slow the pace of research and development activities.

Competitive & Market Risk

Both the AMD and MASH markets are highly competitive arenas where global pharmaceutical majors are aggressively developing next-generation therapies, potentially narrowing the window for securing priority positioning at market entry.

In MASH specifically, numerous global players such as Gilead and AbbVie already hold late-stage pipeline assets, which could weaken AngioLab's leverage in partnering negotiations.

Disputes or unforeseen contract modifications with existing technology-transfer partners represent an additional variable that could affect pipeline development and business continuity.

Overall view

AngioLab is a highly focused R&D enterprise built on angiogenesis-inhibition technology, and it has entered a credible mid-to-long-term value verification trajectory with ALS-L1023's progression into Phase 3 wet-AMD trials and the completion of a 21-country European patent portfolio.

The KRW 11-billion technology-transfer structure with Hallim Pharmaceutical defines a concrete revenue-milestone roadmap, while the multi-indication platform spanning MASH, rosacea, and other conditions provides a meaningful degree of single-program risk diversification.

Nevertheless, the combination of approximately KRW 500 million in annual revenues, persistent operating losses, extremely thin KONEX market liquidity, and the inherent uncertainty of Phase 3 clinical outcomes collectively demands a cautious analytical stance in the near term.

Phase 3 interim data readouts, progress toward a global MASH partnering deal, and any renewed KOSDAQ listing push are the primary catalysts for enterprise value re-rating over the near-to-medium term.

Given the limited information accessibility and trading liquidity characteristic of small-cap KONEX companies, this report is intended for informational purposes based on publicly available disclosures and media coverage, and independent in-depth analysis is warranted prior to any investment consideration.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 9 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.